Clarity Pharmaceuticals Accelerates Prostate Cancer Imaging with FDA Fast Track Nod

• FDA grants second Fast Track Designation for 64Cu-SAR-bisPSMA targeting biochemical recurrence of prostate cancer
• 64Cu-SAR-bisPSMA offers superior lesion detection and next-day imaging flexibility compared to current PSMA PET agents
• Phase III AMPLIFY trial set to commence soon, pivotal for FDA approval
• Potential to capture a growing US$3 billion prostate cancer diagnostic market by 2029